BioXcel Therapeutics files for Chapter 11, agrees to sell assets to Teva
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
August 28, 2026 6:00 AM EDTBioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders
Teva Pharmaceuticals to serve as stalking horse bidder in a court-supervised 363 auction process
BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations
NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (BioXcel Therapeutics or the Company), a biopharmaceutical company built on artificial intelligence (AI) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement... More
